Karyopharm Therapeutics (NASDAQ:KPTI) – Cantor Fitzgerald raised their FY2018 EPS estimates for Karyopharm Therapeutics in a report released on Tuesday, May 22nd. Cantor Fitzgerald analyst M. Goldstein now forecasts that the company will post earnings of ($2.67) per share for the year, up from their previous forecast of ($3.24). Cantor Fitzgerald currently has a “Buy” rating and a $18.00 target price on the stock.
Other equities analysts have also issued reports about the stock. ValuEngine raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Wedbush lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating in a report on Thursday. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 17th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, April 10th. Finally, BidaskClub lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 3rd. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $21.10.
Karyopharm Therapeutics opened at $19.06 on Thursday, MarketBeat reports. The company has a market cap of $938.18 million, a PE ratio of -6.78 and a beta of 3.62. Karyopharm Therapeutics has a 1-year low of $7.48 and a 1-year high of $20.39.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, May 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.11). The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $4.59 million.
Institutional investors and hedge funds have recently made changes to their positions in the business. Teacher Retirement System of Texas acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth $115,000. Alliancebernstein L.P. boosted its stake in Karyopharm Therapeutics by 172.7% during the 4th quarter. Alliancebernstein L.P. now owns 118,430 shares of the company’s stock worth $1,137,000 after purchasing an additional 75,000 shares during the last quarter. Palo Alto Investors LLC boosted its stake in Karyopharm Therapeutics by 1.3% during the 4th quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock worth $34,027,000 after purchasing an additional 45,854 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Karyopharm Therapeutics by 7.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 150,289 shares of the company’s stock worth $1,443,000 after purchasing an additional 9,929 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Karyopharm Therapeutics by 6.4% during the 4th quarter. Franklin Resources Inc. now owns 3,337,569 shares of the company’s stock worth $32,041,000 after purchasing an additional 200,310 shares during the last quarter. 61.44% of the stock is currently owned by institutional investors.
In related news, EVP Christopher Brett Primiano sold 2,000 shares of Karyopharm Therapeutics stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $18.01, for a total value of $36,020.00. Following the sale, the executive vice president now owns 675 shares of the company’s stock, valued at approximately $12,156.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $16.15, for a total transaction of $161,500.00. Following the sale, the insider now directly owns 723,510 shares in the company, valued at approximately $11,684,686.50. The disclosure for this sale can be found here. Insiders sold a total of 67,000 shares of company stock worth $1,067,320 in the last three months. 13.26% of the stock is owned by corporate insiders.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.